Sinopharm Group Co (HK:1099) has released an update.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Sinopharm Group Co.’s subsidiary, SINOPHARM (CNCM LTD), reported a 4.1% increase in revenue, reaching over 38 billion yuan for the first nine months of 2024. Despite this growth, net cash flow from operating activities saw a dramatic decline. Investors might find the modest rise in net profit and earnings per share noteworthy amidst these mixed financial indicators.
For further insights into HK:1099 stock, check out TipRanks’ Stock Analysis page.